FDMT
NASDAQ · Biotechnology
4D Molecular Therapeutics In
$10.14
+0.21 (+2.11%)
Financial Highlights (FY 2026)
Revenue
84.00M
Net Income
-138,115,132
Gross Margin
—
Profit Margin
-164.4%
Rev Growth
+200.8%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 28.7% | 28.7% |
| Operating Margin | -187.2% | -456,911.7% | -31.5% | -30.2% |
| Profit Margin | -164.4% | -413,039.5% | -25.3% | -27.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 84.00M | 286.9K | 228.58M | 262.66M |
| Gross Profit | — | — | 65.62M | 75.40M |
| Operating Income | -157,274,745 | -1,310,696,957 | -72,020,646 | -79,353,945 |
| Net Income | -138,115,132 | -1,099,890,361 | -57,732,834 | -71,516,444 |
| Gross Margin | — | — | 28.7% | 28.7% |
| Operating Margin | -187.2% | -456,911.7% | -31.5% | -30.2% |
| Profit Margin | -164.4% | -413,039.5% | -25.3% | -27.2% |
| Rev Growth | +200.8% | -87.3% | +10.3% | +10.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 29.62M | 33.00M |
| Total Equity | — | — | 238.80M | 269.31M |
| D/E Ratio | — | — | 0.12 | 0.12 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -152,682,720 | -1,322,641,633 | -107,016,126 | -112,376,502 |
| Free Cash Flow | — | — | -89,291,698 | -82,297,413 |